Featured Story

Cancer Genetics makes strides in $14M deal for Response Genetics

Cancer Genetics got approval from a U.S. bankruptcy court in Delaware to purchase Response Genetics, almost two months after the company emerged as the highest bidder in an auction sale of Response's long-beleaguered business.

Illumina expands in China with cancer Dx deal

Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.

Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers

Ilumina kicked off commercialization of its next-generation solid tumor sequencing panel to help researchers identify 15 commonly mutated genes in samples.

OraSure reels in $7.2M from HHS for rapid Ebola test

OraSure Technologies scored an additional $7.2 million from the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research Development Authority (BARDA) for its rapid Ebola test, building on a $10.4 million contract that it signed with BARDA in June 2015.

Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate

Pharma bigwigs Merck KGaA and Pfizer announced they are collaborating with Dako to develop a companion diagnostic to accompany their investigational immune checkpoint inhibiting candidate in the fight against cancer.


From Our Sister Sites


Axovant Sciences, rolling the dice on a once-failed Alzheimer's disease treatment, kicked off its big Phase III trial, a make-or-break effort that could spawn a blockbuster drug or liquidate the company's value.

FiercePharma Manufacturing

Drug sourcing and distribution behemoth AmerisourceBergen figures that the best way to source compounded drugs for its hospital clients is to manufacture them itself. To do that, company will shell out more than $2.5 billion to buy one of the largest sterile drug compounders in the U.S.